Lilly Begins Sales of Jentadueto, a Combo Drug for Type 2s


By: Diabetes Health Staff

Eli Lilly and Company has begun US sales of Jentadueto, a drug for type 2 diabetes that combines Tradjenta and metformin. The drug, in tablet form, is taken twice daily and is available in three prescription strengths.

Tradjenta (linagliptin) is a DPP-4 inhibitor that regulates insulin levels. The drug was introduced less than a year ago to the US market.

Metformin, which regulates the liver’s glucose production, is an older standby drug that physicians often prescribe as the first drug therapy for recently diagnosed type 2s.

Lilly developed Tradjenta in conjunction with German drug maker Boehringer Ingelheim.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.